P059 Ranolazine administered after trastuzumab treatment prevents cardiotoxicity in mice

and on the EndoPredict as well as on the MammaPrint test results were compared. In comparison to the clinical-pathological prognostic markers the EndoPredict would lead to a change of therapy in 36.4% (16/44). Conclusion: It was noticeable that the amount of recommendations for chemotherapy grew by one-third, which is in contrast to all studies published so far. One reason could be a selection bias of the sample cohort because of the high amount of tumours with a grading of 3. If the choice of therapy would base on the MammaPrint result the EndoPredict would lead to a change of therapy in 37.5% (15/40). Both tests lead to different risk classification in 34.2% of patients. Our results shed doubt on the reliability of the current gene expression tests. Follow-up of our patients for extended time periods will be necessary to properly assess the value of the assays. Disclosure of Interest: No significant relationships.